A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences

Abeer M. Shaaban, Graham R. Ball, Rebecca A. Brannan, G. Cserni, Anna Di Benedetto, Jo Dent, Laura Fulford, Helen Honarpisheh, Lee Jordan, J. Louise Jones, Rani Kanthan, Loaie Maraqa, Maria Litwiniuk, Marcella Mottolese, Steven Pollock, Elena Provenzano, Philip R. Quinlan, Georgina Reall, Sami Shousha, Mark StephensEldo T. Verghese, Rosemary A. Walker, Andrew M. Hanby, Valerie Speirs

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Male breast cancer remains understudied despite evidence of rising incidence. Using a co-ordinated multi-centre approach, we present the first large scale biomarker study to define and compare hormone receptor profiles and survival between male and female invasive breast cancer. We defined and compared hormone receptor profiles and survival between 251 male and 263 female breast cancers matched for grade, age, and lymph node status. Tissue microarrays were immunostained for ERα, ERβ1, -2, -5, PR, PRA, PRB and AR, augmented by HER2, CK5/6, 14, 18 and 19 to assist typing. Hierarchical clustering determined differential nature of influences between genders. Luminal A was the most common phe-notype in both sexes. Luminal B and HER2 were not seen in males. Basal phenotype was infrequent in both. No differences in overall survival at 5 or 10 years were observed between genders. Notably, AR-positive luminal A male breast cancer had improved overall survival over female breast cancer at 5 (P = 0.01, HR = 0.39, 95% CI = 0.26-0.87) but not 10 years (P = 0.29, HR = 0.75, 95% CI = 0.46-1.26) and both 5 (P = 0.04, HR = 0.37, 95% CI = 0.07-0.97) and 10 years (P = 0.04, HR = 0.43, 95% CI = 0.12-0.97) in the unselected group. Hierarchical clustering revealed common clusters between genders including total PR-PRA-PRB and ERβ1/2 clusters. A striking feature was the occurrence of ERα on distinct clusters between genders. In female breast cancer, ERα clustered with PR and its isoforms; in male breast cancer, ERα clustered with ERβ isoforms and AR. Our data supports the hypothesis that breast cancer is biologically different in males and females suggesting implications for clinical management. With the incidence of male breast cancer increasing this provides impetus for further study.

Original languageEnglish
Pages (from-to)949-958
Number of pages10
JournalBreast Cancer Research and Treatment
Volume133
Issue number3
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Male Breast Neoplasms
Biomarkers
Breast Neoplasms
Cluster Analysis
Protein Isoforms
Hormones
Incidence
Lymph Nodes
Phenotype

Keywords

  • Androgen receptor
  • Hierarchical clustering
  • Hormone receptors
  • Male breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. / Shaaban, Abeer M.; Ball, Graham R.; Brannan, Rebecca A.; Cserni, G.; Di Benedetto, Anna; Dent, Jo; Fulford, Laura; Honarpisheh, Helen; Jordan, Lee; Jones, J. Louise; Kanthan, Rani; Maraqa, Loaie; Litwiniuk, Maria; Mottolese, Marcella; Pollock, Steven; Provenzano, Elena; Quinlan, Philip R.; Reall, Georgina; Shousha, Sami; Stephens, Mark; Verghese, Eldo T.; Walker, Rosemary A.; Hanby, Andrew M.; Speirs, Valerie.

In: Breast Cancer Research and Treatment, Vol. 133, No. 3, 06.2012, p. 949-958.

Research output: Contribution to journalArticle

Shaaban, AM, Ball, GR, Brannan, RA, Cserni, G, Di Benedetto, A, Dent, J, Fulford, L, Honarpisheh, H, Jordan, L, Jones, JL, Kanthan, R, Maraqa, L, Litwiniuk, M, Mottolese, M, Pollock, S, Provenzano, E, Quinlan, PR, Reall, G, Shousha, S, Stephens, M, Verghese, ET, Walker, RA, Hanby, AM & Speirs, V 2012, 'A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences', Breast Cancer Research and Treatment, vol. 133, no. 3, pp. 949-958. https://doi.org/10.1007/s10549-011-1856-9
Shaaban, Abeer M. ; Ball, Graham R. ; Brannan, Rebecca A. ; Cserni, G. ; Di Benedetto, Anna ; Dent, Jo ; Fulford, Laura ; Honarpisheh, Helen ; Jordan, Lee ; Jones, J. Louise ; Kanthan, Rani ; Maraqa, Loaie ; Litwiniuk, Maria ; Mottolese, Marcella ; Pollock, Steven ; Provenzano, Elena ; Quinlan, Philip R. ; Reall, Georgina ; Shousha, Sami ; Stephens, Mark ; Verghese, Eldo T. ; Walker, Rosemary A. ; Hanby, Andrew M. ; Speirs, Valerie. / A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. In: Breast Cancer Research and Treatment. 2012 ; Vol. 133, No. 3. pp. 949-958.
@article{0559284b06af4c2a97e9b9c0f427c8e5,
title = "A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences",
abstract = "Male breast cancer remains understudied despite evidence of rising incidence. Using a co-ordinated multi-centre approach, we present the first large scale biomarker study to define and compare hormone receptor profiles and survival between male and female invasive breast cancer. We defined and compared hormone receptor profiles and survival between 251 male and 263 female breast cancers matched for grade, age, and lymph node status. Tissue microarrays were immunostained for ERα, ERβ1, -2, -5, PR, PRA, PRB and AR, augmented by HER2, CK5/6, 14, 18 and 19 to assist typing. Hierarchical clustering determined differential nature of influences between genders. Luminal A was the most common phe-notype in both sexes. Luminal B and HER2 were not seen in males. Basal phenotype was infrequent in both. No differences in overall survival at 5 or 10 years were observed between genders. Notably, AR-positive luminal A male breast cancer had improved overall survival over female breast cancer at 5 (P = 0.01, HR = 0.39, 95{\%} CI = 0.26-0.87) but not 10 years (P = 0.29, HR = 0.75, 95{\%} CI = 0.46-1.26) and both 5 (P = 0.04, HR = 0.37, 95{\%} CI = 0.07-0.97) and 10 years (P = 0.04, HR = 0.43, 95{\%} CI = 0.12-0.97) in the unselected group. Hierarchical clustering revealed common clusters between genders including total PR-PRA-PRB and ERβ1/2 clusters. A striking feature was the occurrence of ERα on distinct clusters between genders. In female breast cancer, ERα clustered with PR and its isoforms; in male breast cancer, ERα clustered with ERβ isoforms and AR. Our data supports the hypothesis that breast cancer is biologically different in males and females suggesting implications for clinical management. With the incidence of male breast cancer increasing this provides impetus for further study.",
keywords = "Androgen receptor, Hierarchical clustering, Hormone receptors, Male breast cancer",
author = "Shaaban, {Abeer M.} and Ball, {Graham R.} and Brannan, {Rebecca A.} and G. Cserni and {Di Benedetto}, Anna and Jo Dent and Laura Fulford and Helen Honarpisheh and Lee Jordan and Jones, {J. Louise} and Rani Kanthan and Loaie Maraqa and Maria Litwiniuk and Marcella Mottolese and Steven Pollock and Elena Provenzano and Quinlan, {Philip R.} and Georgina Reall and Sami Shousha and Mark Stephens and Verghese, {Eldo T.} and Walker, {Rosemary A.} and Hanby, {Andrew M.} and Valerie Speirs",
year = "2012",
month = "6",
doi = "10.1007/s10549-011-1856-9",
language = "English",
volume = "133",
pages = "949--958",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences

AU - Shaaban, Abeer M.

AU - Ball, Graham R.

AU - Brannan, Rebecca A.

AU - Cserni, G.

AU - Di Benedetto, Anna

AU - Dent, Jo

AU - Fulford, Laura

AU - Honarpisheh, Helen

AU - Jordan, Lee

AU - Jones, J. Louise

AU - Kanthan, Rani

AU - Maraqa, Loaie

AU - Litwiniuk, Maria

AU - Mottolese, Marcella

AU - Pollock, Steven

AU - Provenzano, Elena

AU - Quinlan, Philip R.

AU - Reall, Georgina

AU - Shousha, Sami

AU - Stephens, Mark

AU - Verghese, Eldo T.

AU - Walker, Rosemary A.

AU - Hanby, Andrew M.

AU - Speirs, Valerie

PY - 2012/6

Y1 - 2012/6

N2 - Male breast cancer remains understudied despite evidence of rising incidence. Using a co-ordinated multi-centre approach, we present the first large scale biomarker study to define and compare hormone receptor profiles and survival between male and female invasive breast cancer. We defined and compared hormone receptor profiles and survival between 251 male and 263 female breast cancers matched for grade, age, and lymph node status. Tissue microarrays were immunostained for ERα, ERβ1, -2, -5, PR, PRA, PRB and AR, augmented by HER2, CK5/6, 14, 18 and 19 to assist typing. Hierarchical clustering determined differential nature of influences between genders. Luminal A was the most common phe-notype in both sexes. Luminal B and HER2 were not seen in males. Basal phenotype was infrequent in both. No differences in overall survival at 5 or 10 years were observed between genders. Notably, AR-positive luminal A male breast cancer had improved overall survival over female breast cancer at 5 (P = 0.01, HR = 0.39, 95% CI = 0.26-0.87) but not 10 years (P = 0.29, HR = 0.75, 95% CI = 0.46-1.26) and both 5 (P = 0.04, HR = 0.37, 95% CI = 0.07-0.97) and 10 years (P = 0.04, HR = 0.43, 95% CI = 0.12-0.97) in the unselected group. Hierarchical clustering revealed common clusters between genders including total PR-PRA-PRB and ERβ1/2 clusters. A striking feature was the occurrence of ERα on distinct clusters between genders. In female breast cancer, ERα clustered with PR and its isoforms; in male breast cancer, ERα clustered with ERβ isoforms and AR. Our data supports the hypothesis that breast cancer is biologically different in males and females suggesting implications for clinical management. With the incidence of male breast cancer increasing this provides impetus for further study.

AB - Male breast cancer remains understudied despite evidence of rising incidence. Using a co-ordinated multi-centre approach, we present the first large scale biomarker study to define and compare hormone receptor profiles and survival between male and female invasive breast cancer. We defined and compared hormone receptor profiles and survival between 251 male and 263 female breast cancers matched for grade, age, and lymph node status. Tissue microarrays were immunostained for ERα, ERβ1, -2, -5, PR, PRA, PRB and AR, augmented by HER2, CK5/6, 14, 18 and 19 to assist typing. Hierarchical clustering determined differential nature of influences between genders. Luminal A was the most common phe-notype in both sexes. Luminal B and HER2 were not seen in males. Basal phenotype was infrequent in both. No differences in overall survival at 5 or 10 years were observed between genders. Notably, AR-positive luminal A male breast cancer had improved overall survival over female breast cancer at 5 (P = 0.01, HR = 0.39, 95% CI = 0.26-0.87) but not 10 years (P = 0.29, HR = 0.75, 95% CI = 0.46-1.26) and both 5 (P = 0.04, HR = 0.37, 95% CI = 0.07-0.97) and 10 years (P = 0.04, HR = 0.43, 95% CI = 0.12-0.97) in the unselected group. Hierarchical clustering revealed common clusters between genders including total PR-PRA-PRB and ERβ1/2 clusters. A striking feature was the occurrence of ERα on distinct clusters between genders. In female breast cancer, ERα clustered with PR and its isoforms; in male breast cancer, ERα clustered with ERβ isoforms and AR. Our data supports the hypothesis that breast cancer is biologically different in males and females suggesting implications for clinical management. With the incidence of male breast cancer increasing this provides impetus for further study.

KW - Androgen receptor

KW - Hierarchical clustering

KW - Hormone receptors

KW - Male breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84863728437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863728437&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1856-9

DO - 10.1007/s10549-011-1856-9

M3 - Article

C2 - 22094935

AN - SCOPUS:84863728437

VL - 133

SP - 949

EP - 958

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -